These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 8562348)

  • 1. Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen.
    Bonnefoi H; Smith IE; O'Brien ME; Seymour MT; Powles TJ; Allum WH; Ebbs S; Baum M
    Br J Cancer; 1996 Feb; 73(3):391-6. PubMed ID: 8562348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen.
    Jones AL; Smith IE; O'Brien ME; Talbot D; Walsh G; Ramage F; Robertshaw H; Ashley S
    J Clin Oncol; 1994 Jun; 12(6):1259-65. PubMed ID: 8201387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer.
    Eisen T; Smith IE; Johnston S; Ellis PA; Prendiville J; Seymour MT; Walsh G; Ashley S
    J Clin Oncol; 1998 Apr; 16(4):1350-7. PubMed ID: 9552036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infusional ECarboF in patients with advanced breast cancer: a very active and well-tolerated out-patient regimen.
    Hügli A; Sappino AP; Anchisi S; Mermillod B; Schafer P; Anguenot JL; Bonnefoi H
    Ann Oncol; 2000 Dec; 11(12):1557-61. PubMed ID: 11205463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.
    Bonnefoi H; Biganzoli L; Cufer T; Mauriac L; Hamilton A; Schaefer P; Piccart M
    Breast Cancer Res Treat; 2001 Nov; 70(1):55-63. PubMed ID: 11768362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type.
    Taamma A; Fandi A; Azli N; Wibault P; Chouaki N; Hasbini A; Couteau C; Armand JP; Cvitkovic E
    Cancer; 1999 Oct; 86(7):1101-8. PubMed ID: 10506692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) in locally advanced or metastatic gastric cancer: a single institution experience.
    Aitini E; Rabbi C; Mambrini A; Cavazzini G; Pari F; Zamagni D; Cantore M; Pagani M; Sorio M; Lusenti A; Adami F; Smerieri F
    Tumori; 2001; 87(1):20-4. PubMed ID: 11669552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site.
    Karapetis CS; Yip D; Virik K; Strickland A; Ryder K; Cowling M; Harper PG
    Med Oncol; 2001; 18(1):23-32. PubMed ID: 11778966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer.
    Evans TR; Lofts FJ; Mansi JL; Glees JP; Dalgleish AG; Knight MJ
    Br J Cancer; 1996 May; 73(10):1260-4. PubMed ID: 8630289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
    Balduzzi A; Montagna E; Bagnardi V; Torrisi R; Bertolini F; Mancuso P; Scarano E; Viale G; Veronesi P; Cardillo A; Orlando L; Goldhirsch A; Colleoni M
    Anticancer Drugs; 2009 Mar; 20(3):197-203. PubMed ID: 19182679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer.
    Smith IE; Walsh G; Jones A; Prendiville J; Johnston S; Gusterson B; Ramage F; Robertshaw H; Sacks N; Ebbs S
    J Clin Oncol; 1995 Feb; 13(2):424-9. PubMed ID: 7844604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer.
    Zhang CX; Huang S; Xu N; Fang JW; Shen P; Bao YH; Mou BH; Shi MG; Zhong XL; Xiong PJ
    Anticancer Drugs; 2007 Jun; 18(5):581-6. PubMed ID: 17414627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).
    Colucci G; Romito S; Gebbia V; Pacilio G; Giotta F; Testa A; Pezzella G; Durini E; Agostara B; Cariello S
    Br J Cancer; 1995 Nov; 72(5):1245-50. PubMed ID: 7577476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial.
    Smith IE; A'Hern RP; Coombes GA; Howell A; Ebbs SR; Hickish TF; O'Brien ME; Mansi JL; Wilson CB; Robinson AC; Murray PA; Price CG; Perren TJ; Laing RW; Bliss JM;
    Ann Oncol; 2004 May; 15(5):751-8. PubMed ID: 15111342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report.
    Zaniboni A; Barni S; Labianca R; Marini G; Pancera G; Giaccon G; Piazza E; Signaroldi A; Legnani W; Luporini G
    Cancer; 1995 Nov; 76(10):1694-9. PubMed ID: 8625036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours.
    Ellis PA; Norman A; Hill A; O'Brien ME; Nicolson M; Hickish T; Cunningham D
    Eur J Cancer; 1995 Sep; 31A(10):1594-8. PubMed ID: 7488407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
    Thuss-Patience PC; Kretzschmar A; Repp M; Kingreen D; Hennesser D; Micheel S; Pink D; Scholz C; Dörken B; Reichardt P
    J Clin Oncol; 2005 Jan; 23(3):494-501. PubMed ID: 15659494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).
    Findlay M; Cunningham D; Norman A; Mansi J; Nicolson M; Hickish T; Nicolson V; Nash A; Sacks N; Ford H
    Ann Oncol; 1994 Sep; 5(7):609-16. PubMed ID: 7993836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
    Torrisi R; Balduzzi A; Ghisini R; Rocca A; Bottiglieri L; Giovanardi F; Veronesi P; Luini A; Orlando L; Viale G; Goldhirsch A; Colleoni M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):667-72. PubMed ID: 18064460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer.
    De Boer RH; Eisen TG; Ellis PA; Johnston SR; Walsh G; Ashley S; Smith IE
    Ann Oncol; 2002 Jun; 13(6):889-94. PubMed ID: 12123334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.